References
- LutchmanGKimWRA glass half full: implications of screening for hepatitis C virus in the era of highly effective antiviral therapyHepatology20156151455145825614010
- European Association for Study of LiverEASL clinical practice guidelines: management of hepatitis C virus infectionJ Hepatol201460239242024331294
- PerellóMCFernández-CarrilloCLondoñoMCReactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agentsClin Gastroenterol Hepatol20163565163020330208
- European Medicines Agency (EMA)EMA Reviews Direct-Acting Antivirals for Hepatitis C Review to Investigate Possible Hepatitis B Re-activationLondonEuropean Medicines Agency (EMA)2016 EMA/199242/2016
- CasteraLFornsXAlbertiANon-invasive evaluation of liver fibrosis using transient elastographyJ Hepatol200848583584718334275
- CarriónJAMartínez-BauerECrespoGAntiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective studyJ Hepatol200950471972819217183
- LondoñoM-CPerellóCCabezasJThe addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosisJ Hepatol201562231131625281861
- GrindeBHerpesviruses: latency and reactivation – viral strategies and host responseJ Oral Microbiol20135122766
- PavlopoulouIDPoulopoulouSMelexopoulouCIncidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxisBMC Infect Dis201515128526204926
- El KassasMWifiMNMahdyRHerpes zoster reactivation in patients with chronic hepatitis C under treatment with directly acting antiviral agents: a case seriesArab J Gastroenterol2017181394128320588
- TsangCSPSamaranayakeLPImmune reconstitution inflammatory syndrome after highly active antiretroviral therapy: a reviewOral Dis201016324825619758406